ReviewMedical oncology (Northwood, London, England)2025
Female and male hormonal-dependent malignancies: the role of long non-coding RNAs.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cis-regulatory and long noncoding RNA alterations in breast cancer - current insights, biomarker utility, and the critical need for functional validation.Molecular oncology · 2026Review
- Carcinogenic Medications: A Review of Specific Agents and Molecular Mechanisms of Carcinogenesis.Cancer reports (Hoboken, N.J.) · 2026Review
- The Multi-Target lncRNA-miRNA-mRNA TRIAD in Pancreatic Cancer Diagnosis and Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since their discovery, long non-coding RNAs (lncRNAs) have emerged as critical regulators of diverse biological processes across various tissues. Their dysregulation has been strongly linked to cancer progression. LncRNAs influence key aspects of tumor biology, including cell proliferation, invasion, metastasis, apoptosis, and therapeutic resistance, acting either as oncogenes or tumor suppressors. In hormone-dependent malignancies such as breast and prostate cancers, lncRNAs play pivotal roles by modulating hormone signaling pathways and regulating the expression and activity of hormone receptors, including estrogen (ER), progesterone (PR), and androgen receptors (AR). Despite increasing evidence of their involvement, many of these lncRNAs remain poorly characterized, and their potential as diagnostic markers or therapeutic targets is still under investigation.This review aims to critically synthesize recent advances in the understanding of lncRNAs in hormone-dependent cancers, with a focus on their oncogenic and tumor-suppressive roles, involvement in drug resistance, and clinical relevance. By highlighting both established findings and areas requiring further research, we seek to provide a comprehensive and insightful overview that can inform future therapeutic strategies and translational applications.
Indexed as
Identifiers
40850965What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.